Kadmon Holdings, Inc.
Kadmon Holdings, Inc. (KDMN): 1 pipeline candidate · ~27 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.3 months
0% dilution
Lead: BLA Filed
1 candidate
N/A
N/A
A transparent, data-derived signal for Kadmon Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$70.9M
Quarterly Burn
$27.8M
Runway
27.3 mo
Revenue
$14.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| belumosudil | BLA Filed |
Frequently asked questions
How many drug candidates are in Kadmon Holdings, Inc.'s pipeline?
Kadmon Holdings, Inc. (KDMN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kadmon Holdings, Inc.'s lead drug candidate?
Kadmon Holdings, Inc.'s most advanced tracked candidate is belumosudil (BLA Filed) for chronic graft-versus-host disease (cGVHD).
What is Kadmon Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kadmon Holdings, Inc. has approximately 27.3 months of cash runway.
Who is the CEO of Kadmon Holdings, Inc.?
New York April is the chief executive officer of Kadmon Holdings, Inc. (KDMN).
Get the full picture on Kadmon Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.